Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is in a stable position due to consistent utilization and consumption of ART cycles, strong client retention, and a compelling valuation. However, potential economic uncertainty and competition could impact their business, and changes in government regulations could also be a risk factor. The upcoming implementation of an IVF mandate in California presents a new revenue opportunity, and the company's existing network should give it an advantage in capturing market share.

Bears say

Progyny is a competitive company operating in the reproductive benefits market. However, as its largest clients account for a significant portion of its revenue and a significant number of its clients are in the technology industry, changes to these clients or within the industry could negatively impact the company's financials. Additionally, changes to healthcare laws and regulations could also harm the company's business and operating results. Furthermore, uncertainties in the healthcare industry could lead to adverse impacts on Progyny's business.

Progyny (PGNY) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 9 analysts, Progyny (PGNY) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.